Prescription versus herbal medications for prostate cancer prevention: Why history cannot be allowed to repeat itself in your clinical practice
Tóm tắt
Từ khóa
Tài liệu tham khảo
Eisenberg DM, David RB, Ettner SL, et al.: Trends in alternative medicine use in the United States. JAMA 1998, 280:1569–1575.
Ciocon JO, Ciocon DG, Galindo DJ: Dietary supplements in primary care: botanicals can affect surgical outcomes and follow-up. Geriatrics 2004, 59:20–24.
Bluementhal M: Herb sales down in mainstream market, up in natural food stores. Herbal Gram 2002, 55:60.
Matthews MK Jr: Association of ginkgo biloba with intracerebral hemorrhage Neurology 1998, 50:1933–1934.
Turner RB, Bauer R, Woelkart K, et al.: An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl JMed 2005, 353:341–348. Most recent review of Echinacea angustifolia.
Rose KD, Croissant PD, Parliament CF, Levin MB: Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery 1990, 26:880–882.
Vuksan V, Sievenpiper JL, Koo VY, et al.: American ginseng (Panax quinquefolius L) reduces postpradial glycemia in nondiabetic subjects and subjects with type-2 diabetes mellitus. Arch Intern Med 2000, 160:1009–1013.
Kuo SC, Teng CM, Lee JC, et al.: Antiplatelet components in Panax ginseng. Planta Med 1990, 56:164–167.
NIH State-of-the-Science Panel: National Institutes of Health State-of-the-Science Conference Statement: management of menopause-related symptoms. Ann Intern Med 2005, 142:1003–1013. Offers best discussion of menopause-related symptoms.
North American Menopause Society: Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004, 11:11–33.
Bent S, Kane CJ, Shinohara K, et al.: A randomized, controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia [Abstract #1637]. J Urol 2005, 173(suppl):443.
Garges HP, Varia I, Doraiswamy PM: Cardiac complications and delirium associated with valerian root withdrawal. JAMA 1998,280:1566–1567.
Terris MK, Issa MM, Tacker RJ: Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001, 57:26–29.
Jatoi A, Ellison N, Burch PA, et al.: A phase-II trial of green tea in the treatment of patients with androgen-independent metastatic prostate carcinoma. Cancer 2003, 97:1442–1446.
Tsubono Y, Nishino Y, Komatsu S, et al.: Green tea and the risk of gastric cancer in Japan. N Engl J Med 2001, 344:632–636.
Steinmetz KA, Potter JD: Vegetables, fruit, and cancer: I. Epidemiology. Cancer Causes Control 1991, 2:325–357.
Steinmetz KA, Potter JD: Vegetables, fruit, and cancer: II. Mechanisms. Cancer Causes Control 1991, 2:427–442.
Peto R, Doll R, Buckley JD, Sporn MB: Can dietary beta-carotene materially reduce human cancer rates? Nature 1981, 290:201–208.
World Cancer Research Fund: Food, Nutrition, and the Prevention of ancer: A Global Perspective. Washington D.C.: American Institute for Cancer Research; 1997:136–142.
Schottenfield D, Fraumeni JF Jr: Cancer Epidemiology and Prevention, edn 2. New York: Oxford University Press; 1996.
Lippman SM, Meyskens FL Jr: Vitamin A derivatives in the prevention and treatment of human cancer. J Am Coll Nutr 1988, 7:269–284.
Bryla P, Weyand EH: Role of activated oxygen species in benzo[a]pyrene: DNA adduet formation in vitro. Free Radie Biol Med 1991, 11:17–24.
Salgo MG, Cueto R, Winston GW, Pryor WA: Beta-carotene and its oxidation products have different effects on microsome mediated binding of benzo[a]pyrene to DNA. Free Radie Biol Med 1999, 26:162–173.
van Poppel G: Carotenoids and cancer: an update with emphasis on human intervention studies. EurJ Can 1993, 29A:1335–1344.
Gann PH, Ma J, Giovannucci E, et al.: Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999, 59:1225–1230.
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl JMed 1994, 330:1029–1035.
Heinonen OP, Albanes D, Virtamo J, et al.: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90:440–446.
Omenn GS, Goodman GE, Thornquist MD, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334:1150–1155.
Omenn GS, Goodman GE, Thornquist MD, et al.: Risk factors for lung cancer and for intervention effects in CARET: the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996, 88:1550–1559.
Palozza P, Caviello G, Bartoli GM: Pro-oxidant activity of beta-carotene under 100% oxygen pressure in rat liver microsomes. Free Radic Biol Med 1995, 19:887–892.
Burton GW, Ingold KU: Beta-carotene: an unusual type of lipid antioxidant. Science 1984, 224:569–573.
Terao Y, Yamauchi R, Murakami H, Matsushita S: Inhibitory effects of tocopherols and beta-carotene on singlet oxygen-initiated photooxidation of methyl linoleate and soybean oil. J Food Present 1980, 4:79–93.
Wang XD, Liu C, Bronson RT, et al.: Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke J Natl Cancer Inst 1999, 91:60–66.
DiPaola RS, Zhang H, Lambert GH, et al.: Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998, 339:785–791.
Moyad MA, Pienta KJ, Montie JE: Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urology 1999, 54:319–323.
Pfeifer BL, Pirani JF, Hamann SR, Klippel KF: PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 2000, 85:481–485.
de la Taille A, Buttyan R, Hayek O, et al.: Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000, 164:1229–1234.
Porterfield H: UsToo PC-SPES surveys: review of studies and update of previous survey results. Mol Urol 2000, 4:289–291.
Small EJ, Frohlich MW, Bok R, et al.: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000, 18:3595–3603.
Oh WK, George DJ, Hackmann K, et al.: Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001, 57:122–126.
Guns ES, Goldenberg SL, Brown PN: Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol. Can J Urol 2002, 9:1684–1688.
Sovak M, Seligson AL, Konas M, et al.: Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst 2002, 94:1275–1281.
Fleshner N, Harvey M, Adomat H, et al.: Evidence for contamination of herbal erectile dysfunction products with phospho-diesterase type-5 inhibitors. J Urol 2005, 174:636–641.
Oikawa T, Ashino-Fuse H, Shimamura M, et al.: A novel angiogenic inhibitor derived from Japanese shark cartilage (I): extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett 1990, 51:181–186.
Cassileth BR: Evaluating complementary and alternative therapies for cancer patients. CA Cancer] Clin 1999, 49:362–375.
Moyad MA: The ABCs of Nutrition and Supplements for Prostate Cancer. Chelsea, MI: Sleeping Bear Press; 2000. Very concise review of the use of supplements for the treatment of prostate cancer.
Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998, 16:3649–3655.
Gonzalez JA, Kernen KM, Peters KM, et al: The oral administration of powdered shark cartilage for the treatment of advanced prostate cancer. Abstract presented at the Michigan Urologie Annual Meeting; 1996.
Dupont E, Savard PE, Jourdain C, et al.: Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 1998, 2:146–152.
Berndt SI, Carter HB, Landis PL, et al.: Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer. Nutrition 2005, 21:686–690.
Cameron E, Campbell A: The orthomolecular treatment of cancer: II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 1974, 9:285–315.
Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1976, 73:3685–3689.
Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: re-evaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1978,75:4538–4542.
Creagan ET, Moertel CG, O’Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N Eng J Med 1979, 301:687–690.
Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized, double-blind comparison. N Eng J Med 1985, 312:137–141.
Podmore I, Griffiths HR, Herbert KE, et al.: Vitamin C exhibits pro-oxidant properties. Nature 1998, 392:559.
Agus DB, Vera JC, Golde DW: Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 1999, 59:4555–4558.
Levine ML, Corry-Cantilena C, Wang Y, et al.: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996, 93:3704–3709.
Blanchard J, Tozer TN, Rowland M: Pharmacokinetic perspectives on mega doses of ascorbic acid. Am J Clin Nutr 1997, 66:1165–1171.
Zollinger PE, Tuinebreijer WE, Kreis RW, Breederveld RS: Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomized trial. Lancet 1999, 354:2025–2028.
Jacques PF, Taylor A, Hankinson SE, et al.: Long-term vitamin C supplement use and prevalence of early age-related lens opacities. Am J Clin Nutr 1997, 66:911–916.
Nyyssonen K, Parviainen MT, Salonen R, et al.: Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ 1997, 314:634–638.
Briefel RR, Bialostosky K, Kennedy-Stephenson J, et al.: Zinc intake of the U.S. population: findings from the third National Health and Nutrition Examination Survey, 1988–1994. J Nutr 2000, 130(suppl):1367S-1373S.
Food and Nutrition Board, National Academy of Sciences: Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Co per, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington D.C.:National Academy Press; 2001.
Leitzmann MF, Stampfer MJ, Wu K, et al.: Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2002, 95:1004–1007. Discusses, in detail, the role zinc plays in prostate cancer.
Ishii K, Usui S, Sugimura Y, et al.: Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells. Biol Pharm Bull 2001, 24:226–230.
Ishii K, Usui S, Sugimura Y, et al.: Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001, 92:49–64.
Feng P, Liang JY, Li TL, et al.: Zinc induces mitochondria apoptogenesis in prostate cells. Mol Urol 2000, 4:31–36.
Feng P, Liang JY, Li TL, et al.: Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999, 40:200–207.
Iguchi K, Hamatake M, Ishida R, et al.: Induction of necrosis by zinc in prostate carcinoma cells and identification of proteins increased in association with this induction. Eur J Biochem 1998, 253:766–770.
Zaichick V, Sviridova TV, Zaichick SV: Zinc in the human prostate gland: normal, hyperplasic, and cancerous. Int Urol Nephrol 1997, 29:565–574.
Nemoto K, Kondo Y, Himeno S, et al.: Modulation of telomerase activity by zinc in human prostatic and renal cancer cells. Biochem Pharmacol 2000, 59:401–405.
Sommerfeld HJ, Meeker AK, Piatyszek MA, et al.: Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996, 56:218–222.
Boissier S, Ferreras M, Peyruchaud O, et al.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000, 60:2949–2954.
Holmes MD, Pollak MN, Willett WC, Hankinson SE: Dietary correlates of plasma insulin-like growth factor-1 and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002, 11:852–861.
Prasad AS, Mantzoros CS, Beck FW, et al.: Zinc status and serum testosterone levels of healthy adults. Nutrition 1996, 12:344–348.
Lagiou P, Wuu J, Trichopoulou A, et al.: Diet and benign prostatic hyperplasia: a study in Greece. Urology 1999, 54:284–290.
Dunzendorfer U, Drahovsky D: C-peptide, testosterone, estrogen, cortisol, and zinc in patients with benign prostatic hyperplasia of the prostate Urol Int 1980, 35:369–374.
Feustel A, Wenrich R: Zinc and cadmium in cell fractions of prostatic cancer tissues of different histological grading in comparison to BPH and normal prostate. Urol Res 1984, 12:147–150.
Brys M, Nawrocka AD, Miekos E, et al.: Zinc and cadmium analysis in human prostate neoplasms. Biol Trace Elem Res 1997, 59:145–152.
Leake A, Chrisholm GD, Busuttil A, et al.: Subcellular distribution of zinc in the benign and malignant human prostate: evidence for a direct zinc androgen interaction. Acta Endocrinol (Copenh) 1984, 105:281–288.
Leake A, Chrisholm GD, Habib FK: The effect of zinc on the 5 alpha-reduction of testosterone by the hyperplastic human prostate gland. J Steroid Biochem 1984, 20:651–655.
Sazawai S, Black RE, Bhan MK, et al.: Efficacy of zinc supplementation in reducing the incidence and prevalence of acute diarrhea: a community-based, double-blind, controlled trial. Am] Clin Nutr 1997, 66:413–418.
Prasad AS, Fitzgerald JT, Bao B, et al.: Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate: a randomized, double-blind, placebo-controlled trial. Ann Int Med 2000, 133:245–252.
Macknin ML, Piedmonte M, Calendine C, et al.: Zinc gluconate lozenges for treating the common cold in children: a randomized, controlled trial. JAMA 1998, 279:1962–1967.
Irving JA, Mattman A, Lockitch G, et al.: Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. Can Med Assoc J 2003, 169:129–131.
Samman S, Roberts DC: The effect of zinc supplements on lipoproteins and copper status. Atherosclerosis 1988, 70:247–252.
Schrauzer GN, White DA, Schneider CJ: Inhibition of the genesis of spontaneous mammary tumors in C3H mice: effects of selenium and of selenium-antagonistic elements and their possible role in human breast cancer. Bioinorg Chem 1976, 6:265–270.
Wiygul JB, Evans BR, Peterson BL, et al.: Supplement use among men with prostate cancer. Urology 2005, 66:161–166.
Neuhouser ML, Kristal AR, Patterson RE, et al.: Dietary supplement use in the prostate cancer prevention trial: implications for prevention trials. Nutr Cancer 2001, 39:12–18.
Weinrich SP, Hudson J, Moyad MA, Weinrich MC: Intake of selected nutritional supplements by African-American men. Urology 2004, 64:1094–1097.
Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.
Moyad MA: Lifestyle changes to prevent BPH: heart healthy = prostate healthy. Urol Nurs 2003, 23:439–441.
Moyad MA, Carroll PR: Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention? Urol Clin North Am 2004, 31:289–300.
Moyad MA, Carroll PR: Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention? Urol Clin North Am 2004, 31:301–311.
Demark-Wahnefried W, Robertson CN, Walther PJ, et al.: Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology 2004, 63:900–904.
Moyad MA: Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemo-prevention trial: part I. Urol Oncol 2004, 22:466–471.
Basier J, Piazza GA: Nonsteroidal anti-inflammatory drugs and cydooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004, 171:S59-S63.
Fagelman E, Lowe FC: Herbal medicines in the treatment of benign prostatic hyperplasia. Urol Clin North Am 2002, 29:23–29.